CCSN President & CEO Jackie Manthorne was one of several speakers at the Ontario Lung Association Breathing Policy Forum on Patient Engagement in Public Policy held in Toronto on Sept. 18, 2019.
During this forum on patient group engagement within the drug submission process and patient group engagement within national Pharmacare, Manthorne presented information about CCSN and the dozens of patient group submissions that CCSN has made to the pan-Canadian Oncology Drug Review (pCODR), the Canadian Agency for Drugs and Technologies in Health (CADTH), and the Institut national d’excellence en santé et services sociaux (INESSS). She added that she is particularly proud of one of the most recent submissions to pCODR, when CCSN spearheaded a submission on a new treatment for several cancers, including lung, colorectal, thyroid, sarcoma and childhood cancers, including neuroblastoma, which was the first submission to pCODR for a new treatment for several cancers.
For more information, contact Manthorne at jmanthorne@survivornet.ca.